Marksans Pharma announced the final approval of the Company`s Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg from USFDA. They are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use. This product is generic version of Clartin tablet in the same strength of Bayer Healthcare. Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from hay fever and other allergies.Powered by Capital Market - Live News

Net profit of Marksans Pharma rose 15.80% to Rs 96.72 crore in the quarter ended September 2024 as against Rs 83.52 crore during the previous quarter ended September 2023. Sales rose 20.83% to Rs 641.92 crore in the quarter ended September 2024 as against Rs 531.24 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales641.92531.24 21 OPM %21.1421.45 - PBDT144.11131.32 10 PBT124.60113.77 10 NP96.7283.52 16 Powered by Capital Market - Live News

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 12 November 2024.Powered by Capital Market - Live News

Marksans Pharma announced that he USFDA has issued an Establishment Inspection Report (EIR) for its manufacturing facility located at Verna, Goa and the inspection has now been successfully closed by the USFDA. USFDA has determined that the inspection classification of this facility is �Voluntary Action Indicated� (VAI).Powered by Capital Market - Live News

Marksans Pharma announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live News